Brief: Nektar Therapeutics Announces Completion Of Target Enrollment In Rezolve-Ad Phase 2B Clinical Trial Of Rezpegaldesleukin In Patients With Moderate-To-Severe Atopic Dermatitis
10/01/2025 12:33
Jan 10 (Reuters) - Nektar Therapeutics NKTR.O :
* NEKTAR THERAPEUTICS ANNOUNCES COMPLETION OF TARGET
ENROLLMENT IN
REZOLVE-AD PHASE 2B CLINICAL TRIAL OF REZPEGALDESLEUKIN IN
PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Source text: ID:nPn2hdKTfa
Further company coverage: NKTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says